Safety
Tirzepatide and Surgery or Anaesthesia
Because tirzepatide slows gastric emptying, food can remain in the stomach longer than standard fasting protocols assume, which raises concern about pulmonary aspiration under anaesthesia. Anaesthesia bodies have issued guidance on managing GLP-1 receptor agonists before procedures. Always tell your surgical and anaesthetic team you are taking it.
Key takeaways
- Slowed gastric emptying can leave stomach contents present despite standard fasting.
- This raises pulmonary aspiration concern during sedation or general anaesthesia.
- Anaesthesia professional bodies have issued specific guidance for incretin therapies.
- Always disclose tirzepatide use to surgical, dental, and anaesthetic teams in advance.
- Whether to withhold a dose before a procedure is a clinical decision, not one this site makes.
| Mechanism of concern | Delayed gastric emptying |
|---|---|
| Risk | Pulmonary aspiration under sedation or anaesthesia |
| Applies to | Surgery, endoscopy, some dental and imaging procedures with sedation |
| Action required | Disclose use to the procedural and anaesthetic team in advance |
| Dose withholding | Clinical decision — not published here |
Why does delayed gastric emptying matter under anaesthesia?
Standard preoperative fasting assumes the stomach empties at a predictable rate. Incretin therapies slow that process, so residual gastric contents can be present even after a conventional fasting interval. Under sedation or general anaesthesia, protective airway reflexes are suppressed and residual contents can be aspirated into the lungs — an uncommon but serious complication.
Anaesthesia societies have responded with guidance on assessment and management, which is why disclosure matters more than any rule of thumb.
What should you do before a scheduled procedure?
Tell the surgical, endoscopic, dental, or anaesthetic team that you take tirzepatide, and say so when the procedure is booked rather than on the day. That gives the team time to apply its own protocol, which may involve gastric ultrasound assessment, a modified fasting period, an airway plan, or withholding a dose.
Do not decide independently to skip a dose before a procedure without instruction from the team managing it — that decision belongs with them.
What the evidence shows
- Delayed gastric emptying as a mechanism of aspiration concern.
- Existence of professional anaesthesia guidance for incretin therapies.
What the evidence does not show
- A universal dose-withholding interval — that is a clinical decision.
- That every procedure requires the same precautions.
Related: Contraindications · Side effects
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
Why did anaesthesia bodies issue specific guidance?
Because standard preoperative fasting intervals assume a predictable gastric emptying rate, and incretin therapy breaks that assumption. Residual gastric contents under sedation, with airway reflexes suppressed, create aspiration risk — uncommon but serious. Guidance emerged because clinicians encountered full stomachs in patients who had fasted correctly.
The response has included assessment approaches such as gastric ultrasound, modified fasting periods, and airway planning. What matters for a patient is that these options exist only if the team knows, which makes disclosure at booking rather than on the day the single most useful action.
Which procedures does this affect beyond major surgery?
Anything involving sedation: endoscopy and colonoscopy, some dental procedures, certain imaging, and minor surgical procedures performed under sedation rather than local anaesthetic alone. The relevant question is not the size of the procedure but whether protective airway reflexes will be suppressed.
Patients frequently disclose medication for a scheduled operation and not for a dental appointment, which is where the gap tends to open.
What does this page cover, and what does it deliberately leave out?
This page addresses Gastric emptying and current perioperative guidance, organised around the primary question of tirzepatide before surgery. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Gastric emptying and current perioperative guidance | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide before surgery.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 5 technical terms this page uses, including GLP-1, contraindication, gastric emptying, incretin — in the specific sense used above.
| GLP-1 | Glucagon-like peptide-1. An incretin hormone that slows gastric emptying, signals satiety to the brain, stimulates glucose-dependent insulin release, and suppresses inappropriate glucagon secretion. |
|---|---|
| contraindication | A circumstance in which a drug should not be used at all. For tirzepatide these include a personal or family history of medullary thyroid carcinoma and MEN2. |
| gastric emptying | The rate at which food leaves the stomach. Incretin therapies slow it, which prolongs fullness and is also the mechanism behind much of the nausea and the perioperative aspiration concern. |
| incretin | A gut hormone released in response to food that amplifies insulin secretion. GIP and GLP-1 are the two principal human incretins, and the drug class that mimics them is named after them. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
Frequently asked questions
Do I need to stop tirzepatide before surgery?
That is a decision for your surgical and anaesthetic team. Tell them you take it when the procedure is booked.
Why does it matter for anaesthesia?
Slowed gastric emptying can leave stomach contents present despite standard fasting, raising aspiration risk under sedation.
Does this apply to dental procedures?
It can where sedation is used. Disclose your medication to the team.
What about endoscopy?
Endoscopy teams have specific protocols for incretin therapies — tell them in advance.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.